Drug Trial Radar · NCT06385093
A Study on the Prevention and Treatment of GIOP With Eldecalcitol
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
314
Planned (sponsor's estimate)
Start
Jun 2024
Primary completion
Dec 2025
Study completion Mar 2026
Sponsor
- Lead sponsor
- Chinese SLE Treatment And Research GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing Life oasis public service center
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be a multi-center, randomized, open label, parallel trial conducted in rheumatoid arthritis patients treated with glucocorticoids. After signing the informed consent, all patients will be screened as per the inclusion and exclusion criteria. Estimated 314 eligible patients will be enrolled. The enrolled patients will be randomly assigned to either Eldecalcitol group or Alfacalcidol group in a 1:1 ratio and followed up for 12 months. On-site follow up visits will be conducted at Month 6 and 12 after enrollment. The study is designed to evaluate the efficacy and safety of Eldecalcitol in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.
Conditions
- Rheumatoid Arthritis
- Osteoporosis
- Osteopenia
Interventions
Eldecalcitol capsulesDrug
Oral eldecalcitol 0.75μg daily
Alfacalcidol tabletsDrug
Oral Alfacalcidol 0.5μg daily
Calcium carbonate tabletsDrug
1.5g Calcium carbonate daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline to month 12 in lumbar spine (L1-4) bone mineral density (BMD)Time frame: Baseline and 12 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Aerospace Central Hospital
Beijing, Beijing Municipality, China
Beijing Luhe hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Shijingshan Hospital
Beijing, Beijing Municipality, China
Beijing Shijitan Hospital
Beijing, Beijing Municipality, China
Beijing Shunyi hospital
Beijing, Beijing Municipality, China
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.